Aldeyra Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Aldeyra Therapeutics has a total shareholder equity of $98.3M and total debt of $15.2M, which brings its debt-to-equity ratio to 15.5%. Its total assets and total liabilities are $126.0M and $27.7M respectively.
Key information
15.5%
Debt to equity ratio
US$15.24m
Debt
| Interest coverage ratio | n/a |
| Cash | US$80.33m |
| Equity | US$98.31m |
| Total liabilities | US$27.73m |
| Total assets | US$126.04m |
Recent financial health updates
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Jun 21
Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?
Feb 16Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?
Nov 06Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Mar 26Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Nov 19Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?
Aug 03Recent updates
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Jun 21Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?
Feb 16Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?
Nov 06Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Mar 26Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Nov 19Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment
Sep 14Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization
Aug 04Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?
Aug 03Aldeyra says trial for dry eye disease candidate reached key goals
Jul 12Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Apr 19Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts
Feb 17Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap
Dec 23Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?
Dec 22Financial Position Analysis
Short Term Liabilities: ALDX's short term assets ($125.6M) exceed its short term liabilities ($27.6M).
Long Term Liabilities: ALDX's short term assets ($125.6M) exceed its long term liabilities ($138.9K).
Debt to Equity History and Analysis
Debt Level: ALDX has more cash than its total debt.
Reducing Debt: ALDX's debt to equity ratio has increased from 0% to 15.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALDX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ALDX has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 3.7% each year.